Of all KRAS and NRAS alterations in CRC (SNVs and Indels, CN and RE regardless of annotation as pathogenic or presence in a hotspot), SNVs or Indels in exons 2, 3, and 4 constituted 96.0% and 94.3% of all alterations, respectively (Fig. 2A,B) the majority being present in one of the known amino acid hotspots (Fig. S1A,B). This evidence concerns the gene KRAS and colorectal carcinoma.